We know that throughout the course of the development of the biotechnology industry history has indeed had a habit of repeating itself. Exactly five years ago the industry was digesting the news that New York-based Pfizer Inc. was shelling out a massive $68 billion to acquire Wyeth – a deal that represented at the time one of the largest big pharma-big pharma transactions in almost a decade.